MaxCyte, Inc.: diluted earnings per share

What this measure means

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

Exact concept: us-gaap:EarningsPerShareDiluted. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2019-01-01 to 2025-12-31. The SEC response was captured on 2026-09-20.

Reading these values

This selected numerical history matches Basic earnings per share for the same reporting intervals and original units. The accounting definitions remain distinct. Equal values do not establish that the concepts are interchangeable or explain why they match; filing dates and accessions may differ. Compare the definitions and source filings before combining them.

Context from the filing

MaxCyte's 2024 and 2025 basic and diluted loss EPS are equal because potential common shares are anti-dilutive during losses. The filing describes excluded options and restricted stock units as 16.3 million and 15.4 million shares, respectively; these rounded excluded amounts are not additions to the reported weighted-average denominator. Dollar losses are displayed in thousands, while shares and per-share amounts are unscaled. Read the source filing.

MaxCyte's historical 2020 and 2021 filing reports full dollar losses and unscaled share counts. Options and stock purchase warrants are excluded as anti-dilutive during losses; the note describes 12.9 million and 12.4 million excluded shares, respectively. Those rounded excluded amounts are not additional weighted-average shares. This review covers the two selected years, not the separate 2019 column also shown in the filing. Read the source filing.

Selected filing history

Related financial histories

• MaxCyte, Inc.: total assets
• MaxCyte, Inc.: total liabilities
• MaxCyte, Inc.: stockholders equity
• MaxCyte, Inc.: cash and cash equivalents
• MaxCyte, Inc.: net income or loss
• MaxCyte, Inc.: operating cash flow
• MaxCyte, Inc.: capital expenditure payments
• MaxCyte, Inc.: revenue
• MaxCyte, Inc.: contract revenue excluding tax
• MaxCyte, Inc.: financing cash flow
• MaxCyte, Inc.: investing cash flow
• MaxCyte, Inc.: retained earnings or deficit
• MaxCyte, Inc.: basic weighted-average shares
• MaxCyte, Inc.: diluted weighted-average shares
• MaxCyte, Inc.: basic earnings per share
• MaxCyte, Inc.: net property, plant and equipment
• MaxCyte, Inc.: share-based compensation expense
• MaxCyte, Inc.: operating income or loss
• MaxCyte, Inc.: current assets
• MaxCyte, Inc.: interest expense
• MaxCyte, Inc.: current liabilities
• MaxCyte, Inc.: current accounts payable
• MaxCyte, Inc.: net current accounts receivable
• MaxCyte, Inc.: operating expenses
• MaxCyte, Inc.: net inventory
• MaxCyte, Inc.: gross profit
• MaxCyte, Inc.: research and development expense

Inspect the source

Entity

MaxCyte, Inc. / CIK 0001287098

Captured

2026-09-20T07:49:28.793Z

SEC response SHA-256

bf885643e4ac829812a590e85ffccacb74e5a1dbcbb30dc2694b3cf04e7ecdf9

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

• Get an API key and run your first validation
• Connect the MCP server to your coding assistant
• Inspect the ALPHAC engine on GitHub
• Read the MCP server source and integration examples

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001287098.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))